Warsaw, Ind.-based Zimmer Biomet has already paid €50.00 per share ($55.39) for more than 1.4 million ROSA shares, which is about 58.77% of the Montpellier, France-based company’s stock, to founder & CEO Bertin Nahum, Newfund and other owners. Zimmer Biomet also put up €50.03 ($55.43) for per Medtech’s convertible bonds and €17.17 ($19.02) for its warrants, both of which were owned by Ally Bridge Group.
Zimmer Biomet said it also agreed to launch and all-cash tender offer for the Medtech shares it doesn’t already own, subject to the approval of France’s anti-trust watchdog, the Autorité des Marchés Financiers.
Medtech board members Frank Yu, Fernand Badano and Eric Briole are resigning in connection with the change of control; Nahum is slated to stay on to lead Zimmer Biomet’s robotics program in Montpellier, the company said.
Medtech makes the Rosa Brain and Rosa Spine robot-assisted surgery platforms; the Rosa Spine device won 510(k) clearance from the FDA in January. Both platforms also have CE Mark approval in the European Union.
“Ally Bridge Group has been a true global partner – and helpful to us particularly in China and the U.S.,” Nahum said in prepared remarks.
“This acquisition of Medtech by Zimmer Biomet is a powerful validation of the innovative technologies – and an impressive global commercial footprint – of the company under the leadership of its founder and CEO, Bertin Nahum,” added Yu, founder, CEO & CIO of Ally Bridge Group. “We expect Zimmer Biomet’s industry-leading position to enable Medtech’s innovative minimally invasive surgical robots to reach a much greater number of patients suffering from neurological and spine disorders globally.”
(€1 = $1.10785)
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.